Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CAPS
MCID: CTS005
MIFTS: 42

Catastrophic Antiphospholipid Syndrome (CAPS)

Categories: Blood diseases, Bone diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Catastrophic Antiphospholipid Syndrome

About this section

MalaCards integrated aliases for Catastrophic Antiphospholipid Syndrome:

Name: Catastrophic Antiphospholipid Syndrome 52 58 71
Catastrophic Antiphospholipid Antibody Syndrome 52
Cryopyrin-Associated Periodic Syndromes 71
Thrombotic Storm 52
Catastrophic Aps 58
Caps 58

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Bone diseases Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare systemic and rhumatological diseases
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 D68.6
Orphanet 58 ORPHA464343
UMLS 71 C2316212 C3662487
Sources

Summaries for Catastrophic Antiphospholipid Syndrome

About this section
NIH Rare Diseases : 52 Catastrophic antiphospholipid syndrome (CAPS) is a rare form of antiphospholipid syndrome (APS). In CAPS multiple blood clots form throughout the body over a short period of time (usually within a week). CAPS is a medical emergency, as clots can cause life-threatening multi-organ failure. The cause of CAPS is unknown. A widely accepted explanation is that it is caused by a combination of gene mutations (making one more susceptible to CAPS) and an environmental trigger, such as an infection, trauma, or surgery.

MalaCards based summary : Catastrophic Antiphospholipid Syndrome, also known as catastrophic antiphospholipid antibody syndrome, is related to thrombotic microangiopathy and heparin-induced thrombocytopenia. An important gene associated with Catastrophic Antiphospholipid Syndrome is APOH (Apolipoprotein H), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Formation of Fibrin Clot (Clotting Cascade). The drugs Metformin and Trandolapril have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are homeostasis/metabolism and mortality/aging

Sources

Related Diseases for Catastrophic Antiphospholipid Syndrome

About this section

Diseases related to Catastrophic Antiphospholipid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)
# Related Disease Score Top Affiliating Genes
1 thrombotic microangiopathy 31.4 CFH ADAMTS13
2 heparin-induced thrombocytopenia 30.9 F3 CD40LG
3 antiphospholipid syndrome 30.6 SERPINE1 MTHFR F5 F3 CFH CD40LG
4 hepatic infarction 30.5 F3 APOH
5 splenic infarction 30.2 F3 CD40LG APOH
6 hemolytic-uremic syndrome 30.2 F3 CFH CD40LG ADAMTS13
7 hemolytic anemia 30.2 F3 CFH CD40LG APOH ADAMTS13
8 acquired hemophilia 30.1 F5 F3
9 disseminated intravascular coagulation 30.1 SERPINE1 F5 F3 ADAMTS13
10 malignant hypertension 30.1 CFH ADAMTS13
11 severe pre-eclampsia 30.1 F5 CFH APOH
12 mixed connective tissue disease 30.1 CD40LG APOH ADAMTS13
13 coronary thrombosis 30.1 SERPINE1 F3
14 thrombotic thrombocytopenic purpura 30.0 F3 CFH CD40LG APOH ADAMTS13
15 anuria 30.0 F3 CD40LG ADAMTS13
16 ischemic colitis 29.9 SERPINE1 F5 APOH
17 hemolytic uremic syndrome, atypical 1 29.9 F3 CFH ADAMTS13
18 branch retinal artery occlusion 29.9 MTHFR F3
19 myelitis 29.7 MTHFR CD40LG APOH
20 purpura 29.6 PROC F3 CD40LG APOH ADAMTS13
21 venous insufficiency 29.3 SERPINE1 MTHFR F5
22 central retinal vein occlusion 29.3 MTHFR F5 F3 APOH
23 thrombocytopenia 29.2 SERPINE1 F5 F3 CFH CD40LG APOH
24 intracranial thrombosis 29.2 MTHFR F5 F3 APOH
25 budd-chiari syndrome 29.2 MTHFR F5 F3 APOH
26 placenta disease 29.1 MTHFR F5 F3 APOH
27 purpura fulminans 29.1 PROC F5 F3 APOH
28 retinal artery occlusion 29.0 SERPINE1 MTHFR F5 APOH
29 homocysteinemia 29.0 SERPINE1 MTHFR F5 APOH
30 kidney disease 29.0 SERPINE1 MTHFR F3 CFH
31 systemic lupus erythematosus 29.0 SERPINE1 HLA-DRB4 F3 CFH CD40LG APOH
32 pre-eclampsia 28.8 SERPINE1 MTHFR F5 F3 CD40LG APOH
33 thrombophilia due to thrombin defect 28.6 SERPINE1 PROC MTHFR F5 F3 APOH
34 stroke, ischemic 28.4 SERPINE1 MTHFR F5 F3 APOH ADAMTS13
35 retinal vein occlusion 28.3 SERPINE1 MTHFR F5 F3 CD40LG APOH
36 cerebrovascular disease 28.3 SERPINE1 MTHFR F5 CD40LG APOH ADAMTS13
37 hellp syndrome 28.3 SERPINE1 MTHFR F5 F3 CFH CD40LG
38 protein c deficiency 28.2 SERPINE1 PROC MTHFR F5 APOH
39 patent foramen ovale 28.2 SERPINE1 MTHFR F5 F3 CD40LG APOH
40 pulmonary embolism 27.9 SERPINE1 PROC MTHFR F5 F3 CD40LG
41 thrombophilia 27.8 SERPINE1 PROC MTHFR F5 F3 CD40LG
42 myocardial infarction 27.8 SERPINE1 MTHFR F5 F3 CFH CD40LG
43 protein s deficiency 27.6 SERPINE1 PROC MTHFR F5 F3 APOH
44 thrombosis 27.3 SERPINE1 PROC MTHFR F5 F3 CD40LG
45 thrombophlebitis 27.3 SERPINE1 PROC MTHFR F5 F3 CD40LG
46 lupus erythematosus 10.5
47 autoimmune disease 10.4
48 respiratory failure 10.4
49 viral exanthem 10.4 CD40LG APOH
50 erythema infectiosum 10.4 CD40LG APOH

Graphical network of the top 20 diseases related to Catastrophic Antiphospholipid Syndrome:



Diseases related to Catastrophic Antiphospholipid Syndrome
Sources

Symptoms & Phenotypes for Catastrophic Antiphospholipid Syndrome

About this section

MGI Mouse Phenotypes related to Catastrophic Antiphospholipid Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.61 ADAMTS13 APOH CD40LG CFH F3 F5
2 mortality/aging MP:0010768 9.32 ADAMTS13 APOH CD40LG CFH CRLS1 F3
Sources

Drugs & Therapeutics for Catastrophic Antiphospholipid Syndrome

About this section

Drugs for Catastrophic Antiphospholipid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 473)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Trandolapril Approved Phase 4 87679-37-6 5484727
3
Captopril Approved Phase 4 62571-86-2 44093
4
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
5
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
6
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
7
Didanosine Approved Phase 4 69655-05-6 50599
8
Histamine Approved, Investigational Phase 4 51-45-6 774
9
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
10
Sertraline Approved Phase 4 79617-96-2 68617
11
Citalopram Approved Phase 4 59729-33-8 2771
12
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
13
Topiramate Approved Phase 4 97240-79-4 5284627
14
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
15
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
16
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
17
Povidone Approved Phase 4 9003-39-8
18
Iodine Approved, Investigational Phase 4 7553-56-2 807
19
Povidone-iodine Approved Phase 4 25655-41-8
20
Cocaine Approved, Illicit Phase 4 50-36-2 5760 446220
21
Ziprasidone Approved Phase 4 146939-27-7 60854
22
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
23
Levetiracetam Approved Phase 4 102767-28-2 441341
24
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
25
Simvastatin Approved Phase 4 79902-63-9 54454
26
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
27
Memantine Approved, Investigational Phase 4 19982-08-2 4054
28
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
29
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
30
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
31
tannic acid Approved Phase 4 1401-55-4
32
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
33
Ferrous fumarate Approved Phase 4 141-01-5
34
Sodium citrate Approved, Investigational Phase 4 68-04-2
35 Taurolidine Approved, Investigational Phase 4 19388-87-5
36
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
37
Suvorexant Approved, Investigational Phase 4 1030377-33-3
38
Promethazine Approved, Investigational Phase 4 60-87-7 4927
39
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
40
Colestipol Approved Phase 4 26658-42-4
41
Prazosin Approved Phase 4 19216-56-9 4893
42
Lopinavir Approved Phase 4 192725-17-0 92727
43
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
44
Propranolol Approved, Investigational Phase 4 525-66-6 4946
45
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
46
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
47
Ambrisentan Approved, Investigational Phase 4 177036-94-1 6918493
48
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
49
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
50
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 430)
# Name Status NCT ID Phase Drugs
1 A Randomized , Controlled, Doulbe Blind Placebo Trial To Evaluate The Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
2 Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
3 Acute Haemodynamic Effects of Treatment With ACE-Inhibitors in Patients With Symptomatic Aortic Stenosis (ACCESS) Unknown status NCT00252317 Phase 4 Captopril and Trandolapril;Captopril Test Dose and Trandolapril
4 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD：a Multicentre Randomised Controlled Trial Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
5 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
6 A Double-Blind, Placebo-Controlled, Flexible-Dose Pilot Clinical Trial of Once-Daily Extended-Release Tramadol for the Treatment of PTSD Unknown status NCT01517711 Phase 4 Tramadol;Placebo
7 Treatment of Plantar Fasciitis With Injection af Platelet-rich Plasma Into the Origin of the Plantar Fascia - a Prospective, Randomized and Double Blinded Study. Unknown status NCT01509274 Phase 4
8 Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza. Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
9 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
10 Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands Completed NCT02645916 Phase 4 Danggui-Sayuk-Ga-Osuyu-Saenggang-tang;Placebo: corn starch
11 Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet : a Randomized, Double-blind, Placebo-controlled Trial Completed NCT01664156 Phase 4 Korean red ginseng;Placebo
12 A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence Completed NCT00785616 Phase 4
13 Cathflo Activase (Alteplase) Pediatric Study (CAPS) Completed NCT00307580 Phase 4 Cathflo Activase (Alteplase)
14 Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens Completed NCT00177333 Phase 4 Doxycycline
15 Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD) Completed NCT00203463 Phase 4 topiramate
16 Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia: an 8-week, Randomized, Double-blind, Placebo-controlled Trial Completed NCT00847600 Phase 4
17 A Placebo-controlled Trial of Adjunctive Quetiapine for Refractory PTSD Completed NCT00292370 Phase 4 Open Label (OL) Paroxetine;Placebo;Quetiapine
18 Randomized Clinical Trial to Study the Topiramate Efficacy for Posttraumatic Disorder Treatment Completed NCT00725920 Phase 4 Topiramate;placebo control group
19 An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder Completed NCT02258828 Phase 4 Memantine
20 Prazosin Treatment for Combat Trauma PTSD Nightmares and Sleep Disturbance Completed NCT00108420 Phase 4 Prazosin
21 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
22 Immediate and Delayed Loading of 4.1 mm and 4.8 mm Implants in the Posterior Mandible & Maxilla: A Controlled Randomized Study of Single or 2-4 Unit Restorations Loaded Immediately After Surgery or Four Weeks After Surgery Completed NCT00782171 Phase 4
23 Risperidone Monotherapy in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma: a Double-Blind, Placebo Controlled, Randomized Clinical Trial Completed NCT00208182 Phase 4 Risperidone
24 Locking of Totally Implanted Venous Access Devices and Tunneled Catheters With or Without Heparin: a Randomised Open-labeled Controlled Trial Completed NCT00994136 Phase 4 normal saline
25 Exercise and Phytoestrogens: a Synergistic Effect on Factors Predisposing to CVD in Postmenopausal Women Completed NCT01048606 Phase 4
26 Skin Antisepsis With Chlorhexidine-Alcohol Versus Povidone Iodine-Alcohol, Combined or Not With Use of a Bundle of New Devices, for Prevention of Intravascular-catheter Colonization and Catheter Failure: An Open Label, Single Center, Randomized Controlled, Two-by-two Factorial Trial Completed NCT03757143 Phase 4 Povidone-Iodine-Alcohol;Chlorhexidine-Alcohol
27 Randomized, Controlled, Double Blind Trial to Evaluate Sedation and Quality of Life in High-risk, Critically Ill Patients Treated With Oral Melatonin Completed NCT00470821 Phase 4 Oral melatonin 3mg BID;Placebo
28 Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder Completed NCT01681849 Phase 4 Placebo;Paroxetine
29 Geodon (Ziprasidone) for Posttraumatic Stress Disorder Completed NCT00208208 Phase 4 Ziprasidone
30 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians Completed NCT00208130 Phase 4 Topiramate
31 A Placebo-Controlled Study of Mirtazapine for PTSD in OIF/OEF Veterans Completed NCT00302107 Phase 4 Mirtazapine;Placebo
32 Combined Mirtazapine and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment of Post-traumatic Stress Disorder (PTSD) Completed NCT01178671 Phase 4 Mirtazapine;Sertraline
33 Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study Completed NCT02287038 Phase 4 Atomoxetine 80 MG
34 A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy. Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
35 Evaluation of Clinical and Safety Outcomes Associated With Conversion From Brand-Name to Generic Tacrolimus Products in High Risk Transplant Recipients Completed NCT02014103 Phase 4 Tacrolimus
36 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
37 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. Completed NCT00619723 Phase 4 Citicoline;Placebo
38 Energy Expenditure Assessment of Preterm Infant With Very Low Birth Weight Fed With Human Milk or Preterm Formula Completed NCT00769509 Phase 4
39 Antidepressant Treatment at an Inner City Asthma Clinic Completed NCT01324700 Phase 4 High severity group: Escitalopram;High severity group: Placebo;Low severity group: Escitalopram;Low severity group: Placebo
40 Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
41 Randomized Double-blind Placebo-controlled Trial of Memantine Hydrochloride for the Treatment of Childhood-onset Epileptic Encephalopathies Recruiting NCT03779672 Phase 4 Memantine Hydrochloride 10 mg
42 Taurolidine Citrate and Unfractionated Heparin Combination Versus Unfractionated Heparin Alone in Prevention of Inflammation in Hemodialysis Catheters. Recruiting NCT03539718 Phase 4 Taurolidine heparin;Heparin Sodium
43 Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial Recruiting NCT03830034 Phase 4 Amino Acid chelated iron tab 15 mg;Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
44 Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance inPosttraumatic Stress Recruiting NCT03642028 Phase 4 Suvorexant
45 Effect Of Dexmedetomidine Infusion On Sublingual Microcirculation In Patients Undergoing On Pump Coronary Artery Bypass Graft Surgery Recruiting NCT02714725 Phase 4 Dexmedetomidine;Placebo for Dexmedetomidine normal saline infusion;Propofol infusion
46 Treatment Effect of Colesevelam for Bile Acid Diarrhoea - a Randomised Placebo-controlled Trial Recruiting NCT03876717 Phase 4 Colesevelam Hydrochloride;Placebo oral capsule
47 Propranolol Reactivation Mismatch (PRM) Treatment for PTSD: A Pilot Study Not yet recruiting NCT03652922 Phase 4 Reactivation Mismatch
48 Administration of Prazosin to Prevent PTSD After Sexual Assault Not yet recruiting NCT03997864 Phase 4 Prazosin;Placebos
49 PTSD Symptom Reduction by Propranolol Given After Memory Activation Terminated NCT00645450 Phase 4 Propranolol;Placebo
50 The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study) Terminated NCT02253394 Phase 4 Ambrisentan plus Spironolactone;Ambrisentan plus Placebo

Search NIH Clinical Center for Catastrophic Antiphospholipid Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


anakinra
Sources

Genetic Tests for Catastrophic Antiphospholipid Syndrome

About this section
Sources

Anatomical Context for Catastrophic Antiphospholipid Syndrome

About this section

MalaCards organs/tissues related to Catastrophic Antiphospholipid Syndrome:

40
Brain, Heart, Testes, Lung, Breast, Liver, Bone
Sources

Publications for Catastrophic Antiphospholipid Syndrome

About this section

Articles related to Catastrophic Antiphospholipid Syndrome:

(show top 50) (show all 473)
# Title Authors PMID Year
1
Catastrophic Antiphospholipid Syndrome-Associated Nephropathy in a Systemic Lupus Erythematosus Patient Without Lupus Nephritis. 61
31609535 2020
2
Treatment of Vascular Thrombosis in Antiphospholipid Syndrome: An Update. 61
31994163 2020
3
Massive Right Ventricular Thrombus Secondary to Catastrophic Antiphospholipid Syndrome. 61
31985720 2020
4
More Than Skin Deep: A Case of Catastrophic Antiphospholipid Syndrome. 61
31677977 2019
5
MitraClip Detachment and Recapture in a Patient With Catastrophic Antiphospholipid Syndrome. 61
31563685 2019
6
Simultaneous Left and Right Ventricular Thrombi Caused by Catastrophic Antiphospholipid Syndrome. 61
31356115 2019
7
An in vitro model to mimic the thrombotic occlusion of small vessels in catastrophic antiphospholipid syndrome (CAPS). 61
31701800 2019
8
Insights into the pathogenesis of catastrophic antiphospholipid syndrome. A case report of relapsing catastrophic antiphospholipid syndrome and review of the literature on ischemic colitis. 61
31853731 2019
9
Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome. 61
31808834 2019
10
Plasma exchange in catastrophic antiphospholipid syndrome. 61
31694791 2019
11
Dabigatran for catastrophic antiphospholipid syndrome. 61
31464688 2019
12
Catastrophic Antiphospholipid Syndrome Presenting with Genitourinary Manifestations. 61
31816208 2019
13
Systemic lupus and catastrophic antiphospholipid syndrome manifesting as cardiogenic shock. 61
31451079 2019
14
Thrombotic Storm With Budd-Chiari Syndrome in a Pediatric Patient With Ulcerative Colitis. 61
31832449 2019
15
CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission. 61
31253464 2019
16
Successful treatment of catastrophic antiphospholipid syndrome with therapeutic plasma exchange: a case report. 61
31537477 2019
17
Catastrophic antiphospholipid syndrome in pregnancy: a life-threatening condition. 61
31527209 2019
18
A catastrophic antiphospholipid syndrome complicated with heparin-induced thrombocytopaenia, successfully managed with double filtration plasmapheresis, steroids and a direct thrombin inhibitor. 61
31527216 2019
19
Catastrophic Antiphospholipid Syndrome as a Cause of Severe Gastrointestinal Bleeding. 61
30904512 2019
20
Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. 61
31214910 2019
21
Mortality in patients with systemic lupus erythematosus in Colombia: a case series. 61
30989407 2019
22
Catastrophic antiphospholipid syndrome as a complication of systemic sclerosis. 61
31309781 2019
23
Revisiting the role of therapeutic plasma exchange in the management of catastrophic antiphospholipid syndrome. 61
30720923 2019
24
Catastrophic antiphospholipid syndrome and pregnancy. Clinical report. 61
29284338 2019
25
Catastrophic Antiphospholid Syndrome - An Unusual Case Report. 61
31435147 2019
26
A case-report of successful use of thromboelastography to manage anticoagulation therapy in a patient with concomitant catastrophic antiphospholipid syndrome and heparin-induced thrombocytopenia. 61
31090599 2019
27
A Case of Probable Catastrophic Antiphospholipid Syndrome Treated With Rituximab and Without Anticoagulation. 61
31124923 2019
28
Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. 61
30844561 2019
29
Rare case of catastrophic antiphospholipid syndrome with spontaneous intracranial haemorrhage. 61
30898956 2019
30
Strategies for eliciting and synthesizing evidence for guidelines in rare diseases. 61
30922227 2019
31
High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant. 61
30837214 2019
32
Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy. 61
30833839 2019
33
Tumid lupus erythematosus-like pseudovasculitic lesions in catastrophic antiphospholipid syndrome. 61
30733989 2019
34
Alveolar Hemorrhage, a Rare and Life-Threatening Complication of Catastrophic Antiphospholipid Syndrome. 61
31815030 2019
35
Intracardiac thrombus in a patient with catastrophic antiphospholipid syndrome: an autopsy case report and review of the literature. 61
31496715 2019
36
A probable case of catastrophic antiphospholipid syndrome: Should high-dose steroids be given in the setting of polymicrobial sepsis? 61
30967955 2019
37
Catastrophic antiphospholipid syndrome causing ST-segment elevation myocardial infarction with non-obstructive coronary arteries. 61
30635301 2019
38
Hyperferritinaemia: An Iron Sword of Autoimmunity. 61
31686632 2019
39
Therapeutic Plasma Exchange Outcomes in Cairo University Hospitals: 6 Years Experience. 61
30009495 2018
40
[Case series and clinical analysis of 14 cases of catastrophic antiphospholipid syndrome]. 61
30562777 2018
41
Therapeutic response to glucocorticoids, anticoagulation and plasma exchange in a patient with primary antiphospholipid syndrome presenting with purpura fulminans. 61
30290709 2018
42
Bilateral central retinal artery occlusion from catastrophic antiphospholipid syndrome. 61
30420561 2018
43
Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review. 61
30101319 2018
44
Post-partum catastrophic antiphospholipid syndrome presenting with shock and digital ischaemia - A diagnostic and management challenge. 61
30515245 2018
45
Co-existing Bilateral Pulmonary Embolism and Intra-cardiac Mass: A Case of Catastrophic Antiphospholipid Syndrome-like Disease. 61
30546985 2018
46
Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: A case report. 61
30290624 2018
47
Acute syndrome of pan-epidermolysis and thrombotic storm arising in a patient with systemic lupus erythematosus. 61
30306116 2018
48
Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report. 61
30146007 2018
49
Total penile necrosis as a manifestation of catastrophic antiphospholipid syndrome. 61
31268004 2018
50
[A child of thrombotic storm controlled by rivaroxaban]. 61
30078248 2018
Sources

Variations for Catastrophic Antiphospholipid Syndrome

About this section
Sources

Expression for Catastrophic Antiphospholipid Syndrome

About this section
Search GEO for disease gene expression data for Catastrophic Antiphospholipid Syndrome.
Sources

Pathways for Catastrophic Antiphospholipid Syndrome

About this section

Pathways related to Catastrophic Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 12.63 SERPINE1 PROC F5 F3 APOH
2
Formation of Fibrin Clot (Clotting Cascade) 65
Show member pathways
 11.46 SERPINE1 PROC F5 F3
3
Complement and coagulation cascades 1 36
11.18 SERPINE1 PROC F5 F3 CFH
Sources

GO Terms for Catastrophic Antiphospholipid Syndrome

About this section

Cellular components related to Catastrophic Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 SERPINE1 PROC F5 F3 CFH CD40LG
2 cell surface GO:0009986 9.46 F3 CD40LG APOH ADAMTS13
3 extracellular space GO:0005615 9.23 SERPINE1 PROC F5 F3 CFH CD40LG

Biological processes related to Catastrophic Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.54 SERPINE1 F5 APOH
2 blood coagulation GO:0007596 9.46 PROC F5 F3 ADAMTS13
3 positive regulation of blood coagulation GO:0030194 9.32 SERPINE1 APOH
4 negative regulation of fibrinolysis GO:0051918 9.26 SERPINE1 APOH
5 negative regulation of blood coagulation GO:0030195 9.13 SERPINE1 PROC APOH
6 hemostasis GO:0007599 8.92 PROC F5 F3 ADAMTS13
Sources

Sources for Catastrophic Antiphospholipid Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....